Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Adora Life Science, Inc.Adora Life Science Announces the Appointment of Dr. Clinton D. Morgan as Chief Medical OfficerAdora Life Science (Adora) today announced that Dr. Clinton D. Morgan, MD, will be joining Adora as its full-time Chief Medical Officer, effective November 1, 2026. Dr. Morgan has previously been appointed to Adora's Board of Directors and...
- Flow Neuroscience launches FL-100 in the US, the first FDA-approved at-home tDCS treatment for depressionFlow Neuroscience launches FL-100 in the US, the first FDA-approved at-home tDCS treatment for depression
- Pennant Acquires Real Estate of Mainplace Senior Living in Orange, CaliforniaThe Pennant Group, Inc. (NASDAQ: PNTG), the parent company of Pennant affiliated home health, hospice, home care and senior living companies, announced today that, effective September 3, 2026, it acquired the real estate of Mainplace Senior Living (“Mainplace”), a senior living community located in Orange, California. A Pennant affiliated subsidiary has operated Mainplace under a triple-net lease since our spin-off in 2019. This acquisition aligns with our disciplined approach of capital deployment in acquiring senior living real estate, at attractive pricing, to capture both the long-term value of the real estate that benefits from the strong cultural, clinical and operational results in the acquired community.
- Braveheart Bio to Participate in Stifel Cardiometabolic ForumBraveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Stifel Virtual Cardiometabolic Forum, being held September 30. Management will participate in a fireside chat on Wednesday, September 30, 2026, at 12:30 p.m. EDT.
- ARCPOINT ANNOUNCES RESIGNATION OF BOARD MEMBERARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) reports that David Keys has resigned as a member of the Company’s Board of Directors effective September 14, 2026, in order to devote more time to his other director obligations with other issuers. The Company thanks Mr. Keys for his service and contributions and wishes him all the best in his future endeavors. Following Mr. Keys’ resignation, the Company’s Board of Directors consists of Zelong (“Roger”) He, John Constantine and Adam Ho. The Company is taking steps to identify and appoint additional qualified directors to the Company’s Board of Directors. About ARCpoint Inc. ARCpoint is a healthcare technology company that owns and develops MAPL, a multi-tenant software platform for clinical lab ordering, scheduling and results delivery used by laboratories, collection sites and other healthcare service providers in the United States. ARCpoint’s Class A Subordinate Voting Shares trade on the TSX Venture Exchange under the symbol “ARC” (currently suspended). For more information, please contact:
- Medical Properties Trust, Inc.MPT Completes the Sale of Two Hospitals for $371 Million in CashBIRMINGHAM, Ala., September 16, 2026--Medical Properties Trust, Inc. (the "Company" or "MPT") (NYSE: MPT) today announced the sale of the real estate of Idaho Falls Community Hospital and Mountain View Hospital to affiliates of Intermountain Health, an investment grade not-for-profit health system, for $413 million (the "Transaction"), a 6.9% capitalization rate.
- American Kidney Fund Honors Retiring Members of Congress and Alonzo Mourning During Congressional Black Caucus Foundation ConferenceReception will celebrate leaders and advocates advancing kidney health, raise awareness of kidney disease and its impact on Black communities
- Myosin Therapeutics Inc.Myosin Therapeutics Selected for 2026-2027 NCI Investor Initiatives ShowcaseMyosin Therapeutics, Inc., a clinical-stage biotechnology company developing a new class of therapies targeting cancer cell mechanics, today announced its selection as a 2026–2027 National Cancer Institute (NCI) Investor Initiatives Showcase...
- Alberta Cancer FoundationJack Ady Cancer Centre launches Alberta's first researcher-led cancer clinical trial outside major urban centresDonor-supported study will evaluate whether prostate cancer radiation treatments can be safely reduced from five sessions to two
- ForgeTrialynx Wins Forge’s DPHARM Idol Disrupt 2026This morning, Trialynx was announced as the winner of DPHARM Idol Disrupt at the 16th annual DPHARM: Disruptive Innovations to Modernize Clinical Research 2026 event. DPHARM is a part of Forge’s Fierce Life Sciences.
- Suvoda earns two PM360 Innovation Awards for Sofia AI assistant and Suvoda AppSuvoda wins two PM360 Innovation Awards for Sofia AI assistant for clinical trials, and the Suvoda App, easing burdens for sites, sponsors, and patients.
- Kaplan Fox Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors with Losses to Contact the Firm Before November 2, 2026Kaplan Fox announces a securities class action against Hims & Hers Health (NYSE: HIMS) for investors from Aug. 4, 2025 to July 29, 2026.